Most dry eye supplements start with an ingredient. We start with the target, and work backward to what gets us there.
The chain works like this: food-grade inputs are fermented or biotransformed by the gut ecosystem. This changes microbial metabolites and host-microbe signals. Those circulating signals may influence systemic immune and barrier tone. And the ocular surface may respond.
Food-gradeinputs
Fermentedbiotransformed
Microbialmetabolites, signals
Systemic immunebarrier tone
Ocular surfacemay respond
Five axes, each with its own logic, its own ocular relevance and its own stated boundary. Scroll to move through them.
Gut / host logic
Fermentation and direct SCFA support may influence tight-junction and regulatory immune pathways.
Ocular relevance
Lower systemic inflammatory priming and support for homeostasis.
Boundary / Needs measured metabolites and controlled ocular outcomes.
Gut / host logic
Microbial indoles can signal through receptors involved in barrier and immune biology.
Ocular relevance
Potential support for epithelial and vascular barrier context.
Boundary / Human dry-eye outcome evidence is limited.
Gut / host logic
Resident microbes can convert poorly absorbed precursors into circulating metabolites.
Ocular relevance
Systemic redox and inflammatory signalling.
Boundary / Metabotypes vary; precursor intake does not guarantee a specific metabolite.
Gut / host logic
Selected lipid and small-molecule pathways may support the active resolution of inflammation.
Ocular relevance
Potential reduction in inflammatory burden without a simple suppression claim.
Boundary / Component evidence cannot be transferred automatically to the complete product.
Gut / host logic
Bile-acid, Nrf2, mitochondrial and autophagy-related nodes are tuned by indication.
Ocular relevance
Ocular-surface resilience and tissue homeostasis.
Boundary / Primarily mechanistic or preclinical until measured clinically.
| Design principle | How it appears in dry eye | Why it matters |
|---|---|---|
| Target-first | Metabolite targets and gut-eye pathways are defined before component selection. | Creates a reason for every component and a measurable way to be wrong. |
| Non-live | Microbiota-accessible substrates, defined bioactives and direct metabolites; no administered live organisms. | Improves standardisation and avoids viability/engraftment dependence. |
| Metabolite floor | A direct functional signal sits beneath microbiome-dependent conversion. | Addresses the responder/non-responder problem explicitly. |
| Parsimony | Each component occupies a distinct mechanistic node. | Avoids a long list where recognition substitutes for architecture. |
| Adjunctive | The oral approach occupies an upstream systemic layer alongside local care. | Protects patients and keeps the positioning scientifically honest. |
Target-first
How it appears in dry eye
Metabolite targets and gut-eye pathways are defined before component selection.
Why it matters
Creates a reason for every component and a measurable way to be wrong.
Non-live
How it appears in dry eye
Microbiota-accessible substrates, defined bioactives and direct metabolites; no administered live organisms.
Why it matters
Improves standardisation and avoids viability/engraftment dependence.
Metabolite floor
How it appears in dry eye
A direct functional signal sits beneath microbiome-dependent conversion.
Why it matters
Addresses the responder/non-responder problem explicitly.
Parsimony
How it appears in dry eye
Each component occupies a distinct mechanistic node.
Why it matters
Avoids a long list where recognition substitutes for architecture.
Adjunctive
How it appears in dry eye
The oral approach occupies an upstream systemic layer alongside local care.
Why it matters
Protects patients and keeps the positioning scientifically honest.
The strongest comparison is with approaches, not brands. Existing options should be described respectfully: topical and procedural care are indispensable and act directly where symptoms and tissue injury occur. The Enbiosis proposition is a different layer of intervention, not a better drop.
Where en-TEAR sits
Oral adjunct addressing a distinct systemic hypothesis; never a replacement.
Where en-TEAR sits
We start from a defined gut-eye mechanism and test it against measurable endpoints.
Where en-TEAR sits
Multi-axis design with each component assigned a non-redundant role.
Where en-TEAR sits
Non-live, standardisable inputs plus a direct metabolite floor.
Where en-TEAR sits
Fewer actives, each selected target-first rather than for recognition.
Where en-TEAR sits
Registered trials with objective signs, and null results published alongside the positive ones.
The main measure was Schirmer I, which tracks tear production. We also tracked TBUT, OSDI, DEQ-5, and how often people needed artificial tears.
Primary endpoint · Schirmer I
+0mm
tear production · p<0.001
A clinically meaningful within-participant gain in tear production over eight weeks.
OSDI
Improved
p<0.001
DEQ-5
Improved
p<0.001
Artificial-tear use
Declined
p<0.001
TBUT
No change
p=0.078
NCT07453212
Completion planned before the end of 2026. Recruitment progress is operational evidence of execution, not clinical evidence of efficacy.
No. It is an oral adjunctive concept aimed at an upstream systemic layer; local treatment and ophthalmic assessment remain essential.
We share the full pilot report, the ongoing RCT protocol and the formulation rationale with prospective partners. Book a call and we'll walk you through the data and your territory.
